Effect of nicorandil on serum matrix metalloproteinase-9, vascular endothelial growth factor and vascular endothelial function in patients after coronary intervention / 中国基层医药

ABSTRACT

Objective:To investigate the therapeutic effect of nicorandil on patients with coronary heart disease after interventional therapy, and its influence on serum matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEGF) and vascular endothelial function.Methods:From January 2018 to December 2019, 120 patients with coronary heart disease who underwent percutaneous coronary intervention(PCI) were selected from Jinhua People's Hospital.They were divided into control group (60 cases) and observation group (60 cases) according the random digital table method.The control group received rosuvastatin on the second day after PCI, and the observation group received nicorandil on the second day after PCI.The course of treatment in both two groups was 12 weeks.The treatment effects, cardiac function, MMP-9, VEGF and vascular endothelial function were compared between the two groups before and after treatment.Results:The total effective rate of the observation group[93.33%(56/60)] was higher than that of the control group[75.00%(45/60)](χ 2=7.566, P<0.05). After treatment, the LVEF [(46.97±1.78)%] of the observation group was higher than that of the control group [(43.83±2.19)%], while the LVEDD [(56.14±2.37)mm] and LVESD [(47.83±2.69)mm] of the observation group were lower than those of the control group [(61.08±2.96)mm and (52.37±2.73)mm], and the difference was statistically significant between the two groups( t=8.618, 10.091, 9.176, all P<0.05). The levels of MMP-9 [(2.36±0.43)μg/L] and VEGF [(45.26±6.89)ng/L] in the observation group were lower than those in the control group [(3.74±0.64)μg/L and (58.42±7.21)ng/L] ( t=13.864, 10.221, all P<0.05). The level of serum NO [(62.31±6.98)μmol/L] in the observation group was higher than that in the control group [(54.39±4.51)μmol/L], while ET-1 [(58.74±6.21)μg/L] was lower than that in the control group [(76.29±4.56)μg/L], and the differences were statistically significant between the two groups( t=7.382, 17.645, all P<0.05). Conclusion:Nicorandil is effective in the treatment of patients with coronary heart disease, and can reduce the levels of MMP-9 and VEGF in serum, and improve the function of vascular endothelium.